Loading stock data…
PASG
$5.57+0.07 (+1.27%)
After Hours$5.57+0.00 (+0.00%)· Last close Jun 9
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Passage Bio, Inc. in the Healthcare sector is trading at $5.57. Wall Street consensus targets $11.40 (5 analysts), implying a +104.7% move over the next 12 months. The stock is currently near its 52-week low of $3.94, remaining 34.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +104.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.57
Potential Downside
0%
Whystock Fair Value$5.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficienc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-320.59%
Volume
Today's trading volume
27,518
Recent News
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months. On April 20, Passage Bio said it was reviewing its strategic alternatives to maximize shareholder value. It has tapped Wedbush PacGrow […]
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a r
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
Passage Bio (PASG) is "undervalued" given PBFT02's distinct profile, with the US Food and Drug Admin
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
Intel upgraded, Reddit initiated: Wall Street's top analyst calls